Recent Advances in Anaesthesia and Intensive Care

This is the latest volume of this very successful and long-established series (previously entitled Recent Advances in Anaesthesia and Analgesia) to present a collection of cutting-edge topics for anaesthetists. It has been compiled by some of the world's leading authorities in their subjects and builds on the successful formula of the previous volumes. As the title suggests, these latest volumes have increased the input from the field of intensive care, and the emphasis remains on producing articles of high quality and interest to the reader while providing exceptional value for money.

This volume is a recommended reading for trainee, practising anaesthetists and intensivists at all levels of experience.
Recent Advances in
Anaesthesia and Intensive Care

Edited by

J.N. Cashman BSc, MB BS, BA, MD, FRCA
Consultant Anaesthetist, St George’s Hospital, London
Honorary Senior Lecturer in Anaesthesia
University of London, UK

R.M. Grounds MB BS, MRCS LRCP, MD, FRCA, DA
Consultant in Anaesthesia and Intensive Care Medicine
St George’s Hospital, London
Honorary Reader in Intensive Care Medicine
University of London, UK
Contents

Preface vii
Contributors xi

1. Pharmacogenomics: the genetic basis for variability in drug response
   B.P. Sweeney 1

2. The opioid receptor and opioid peptides
   C. Zöllner, C. Stein 35

3. Coagulation
   M. Laffan 55

4. Anaesthetic agents and myocardial protection
   W. Schlack, D. Ebel 77

5. The treatment of heart failure due to left ventricular systolic dysfunction
   R.S. Gardner, T.A. McDonagh 89

6. Blunt chest trauma
   A.R. Edouard, V. Minville, L. Martin 103

7. Functional haemodynamic monitoring
   R. Chavko, M.R. Pinsky 133

8. Sepsis and the use of Xigris®
   J.-L. Vincent 151
9. Selective decontamination of the digestive tract: why don’t we apply evidence in practice?
   H.K.F. van Saene, N. Taylor, S.P. Barrett, K. Lowry, R.E. Sarginson

10. Glycaemic control and outcome in intensive care
    D. Mesotten, I. Vanhorebeek, G. Van den Berghe

11. Substance use disorders and anaesthesia
    J. Jage, F. Heid

Index
Preface

In this 23rd edition of *Recent Advances in Anaesthesia and Intensive Care*, we bid farewell to our Senior Co-editor Prof. Anthony (Tony) Adams. Tony joined Dr Richard Atkinson for the 15th edition, which appeared in 1985 and has been a co-editor of *Recent Advances* through eight editions over the past 20 years. When Dr Atkinson stepped down as editor, Tony invited Dr Jeremy Cashman to co-edit the 19th edition. Dr Michael Grounds joined the editorial team for the 22nd edition. Tony’s drive, enthusiasm and wisdom born of long experience have been in no small measure instrumental in the continuing popularity of the series. Both of the current editors are grateful to Tony for his wise counsel over the years and for his continuing support, even now when he is no longer an editor. We wish him a long, healthy and happy retirement.

The editors are grateful to the many distinguished colleagues from the USA, Europe and the UK who have contributed to this volume. We have endeavoured to include a range of topics in this issue that represent all aspects of anaesthesia and intensive care. The first four chapters present developments in the basic sciences. There is enormous inter-individual variability in the way patients respond to medications. Indeed, adapting to this heterogeneity is part of the ‘art’ of anaesthesia. Over recent years, huge progress has been made in our understanding of the structure as well as the function of the genome, allowing researchers to explore those genes that express proteins controlling drug action and metabolism. The burgeoning field of pharmacogenomics deals with the various aspects of gene–drug interactions and aims to further elucidate the inherited nature of inter-individual differences in drug disposition and effects. In Chapter 1 *Pharmacogenomics: the genetic basis for variability in drug response*, Dr Sweeney reviews the current status of work in this field, highlights anaesthetic examples and addresses strategies that hold promise for the future; recombinant DNA technology has already resulted in the introduction of
drugs, such as recombinant human activated protein C (Chapter 8) and human insulin (Chapter 9). In Chapter 2 The opioid receptor and opioid peptides, Dr Zöllner and Prof. Stein review recent developments in the understanding of opioid receptors. Molecular cloning has had a tremendous impact on our knowledge of the μ-, δ- and κ-opioid receptors, as well as identifying the opioid-like orphan receptor 1 (ORL-1). Cellular mechanisms of action including opioid receptor desensitization (important in the development of tolerance; Chapter 10) and endogenous ligands are discussed. The functional aspects of opioid use with specific reference to their peripheral antinociceptive effect are considered. Normal haemostasis is achieved by a complex mechanism comprising a balance between pro- and anticoagulant forces. Hereditary or acquired deficiency of factors on either side of this balance may result in a prothrombotic or a haemorrhagic tendency. The system is continually active at a low rate, which allows it to be rapidly responsive to haemorrhagic challenge. Separation of the physiological trigger for coagulation from the effector enzymes in plasma is essential for controlling this system. In Chapter 3 Coagulation, Dr Laffan explains how improved understanding allows us to effectively manipulate this system and treat these disorders for therapeutic benefit. It has become apparent that anaesthetic drugs can influence the heart by augmenting or inhibiting (or indeed having no overall effect) on cardioprotective mechanisms. Prof. Schlack and Dr Ebel, in Chapter 4 Anaesthetic agents and myocardial protection, point out the evidence that cardioprotection by anaesthetic agents can be elicited in the clinical setting and may add to other organ protection strategies. Volatile anaesthetic agents can interfere with ischaemic preconditioning, may act against reperfusion injury and as a result may impact on patient outcome in ischaemia–reperfusion situations.

The next two chapters deal with trauma and emergency medicine topics. As Drs Gardner and McDonagh state in Chapter 5 The treatment of heart failure due to left ventricular systolic dysfunction, heart failure is a serious condition, with a worse prognosis than many forms of cancer, that affects a significant proportion of the population. Until recently, the goal for the treatment of heart failure was to relieve symptoms and enhance functional capacity. However, recent studies have shown that pharmacotherapy with angiotensin converting enzyme inhibitors and β-adrenergic receptor blockade and cardiac resynchronization therapy combined with automatic implantable cardioverter defibrillator implantation can reduce both the morbidity and the mortality of chronic heart failure. Drs Gardner and McDonagh also present the results of recent trials of nesiritide and levosimendan in acute heart failure. Blunt chest trauma remains an extreme clinical challenge, accounting for nearly 25% of all traumatic deaths. Life-threatening chest lesions are frequently associated with extrathoracic
injuries that may contribute to severe, sometimes delayed, cardio-
respiratory failure. However, apparently minor trauma may also be life
threatening. In Chapter 6 Blunt chest trauma, Drs Edouard, Minville and
Martin present the management of this condition, including the use of new
imaging technology in the assessment of trauma patients. A specific, step-
wise therapeutic strategy is outlined.

Two of the primary goals of haemodynamic monitoring are to identify the
presence of circulatory shock and to guide specific goal-directed treat-
ments. In Chapter 7 Functional haemodynamic monitoring Drs Chavko
and Pinsky present recent advances in monitoring techniques and review
clinical trials that support the rationale of applying ‘functional’ measures
of cardiovascular performance to define specific treatment approaches,
rather than just the measurement of static haemodynamic values that may
reflect a variety of disease processes and their potential responsiveness to
treatments. The limitations of the technique are also presented.

The next three chapters consider intensive care topics. Sepsis is one of the
most common disease processes encountered in the critically ill population.
Sepsis has been, and continues to be, the subject of vast amounts of research,
and sepsis therapeutics in particular is a rapidly advancing field. In Chapter
8 Sepsis and the use of Xigris®, Prof. Vincent reviews drotrecogin alfa, a
recombinant form of the natural protein activated protein C (Xigris®). Xigris
is the first immunomodulating drug to be shown to directly influence
outcome in patients with severe sepsis and septic shock. The next chapter
presents another approach to the problem of infection, acquired either before
or after admission to the intensive care unit (ICU). The purpose of selective
decontamination of the digestive tract is to prevent or eradicate oropharyn-
geal and gastrointestinal carriage of potentially pathogenic micro-organisms,
leaving the indigenous flora predominantly undisturbed. In Chapter 9
Selective decontamination of the digestive tract: why don’t we apply evidence
in practice? Drs van Saene, Taylor, Barrett, Lowry and Sarginson review the
evidence in favour of selective decontamination and propose a radical
rethinking of the philosophy by which antimicrobials are used. In the past,
hyperglycaemia was considered to be an adaptive stress response, and a rise
in blood sugar in critical illness was only treated when blood glucose levels
became excessive. However, a recent study clearly established the beneficial
effects of strictly maintaining normoglycaemia in ICU patients. Intensive
insulin therapy was associated with a remarkable reduction in mortality of
ICU patients, particularly in patients with prolonged critical illness. In
Chapter 10 Glycaemic control and outcome in intensive care, Drs Mesotten,
Vanhorebeek and Van den Berghe discuss the mechanisms for this action and
describe a regimen for maintaining strict glycaemic control.
Anaesthesia and postoperative analgesia in patients dependent on psychoactive substances poses special problems. These patients commonly suffer from co-existent medical and psychiatric illness. In Chapter 11 *Substance use disorders and anaesthesia*, Prof. Jage introduces the concept of substance use disorders with central nervous system depressant and stimulant substances. The neural basis of addiction is described and the anaesthetic and analgesic management of patients with substance use disorders and ex-addicts is outlined in detail.

This edition of Recent Advances aims to afford practising anaesthetists the opportunity to keep abreast of some of the latest developments in our speciality. In addition, the editors feel that it is important that the present volume addresses the whole scope of our speciality from the laboratory to the operating theatre. We hope that readers not only find the chapters in this issue stimulating and interesting but also agree with this approach.

London

July 2004

J.N.C.

R.M.G.
Contributors

Dr S.P. Barrett
Department of Bacteriology
Charing Cross Hospital
Fulham Palace Road
London, W6 8RF
UK

Prof. Greet Van den Berghe
Professor and Head of Department of Intensive Care Medicine
University Hospital Gasthuisberg
University of Leuven
B-3000 Leuven
Belgium

Dr R. Chavko
University of Pittsburgh School of Medicine
606 Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15261
USA

Dr D. Ebel
Klinik fur Anaesthesiologie
Universitätsklinikum Düsseldorf
Moorenstrasse 5
40225 Düsseldorf
Germany

Dr A. Edouard
Service d’Anesthésie-Réanimation
Centre Hospitalier de Bicêtre
94275 Le Kremlin Bicêtre
France
Contributors

Dr R.S. Gardner
Department of Medical Cardiology
University of Glasgow
Glasgow Royal Infirmary
10 Alexandra Parade
Glasgow G31 2ER
UK

Prof. Dr Jurgen Jage
Director of Pain Services
Klinik fur Anaesthesiologie
University Hospital Mainz
Langenbeckstrasse 1, 5513
Mainz
Germany

Dr Michael Laffan
Department of Haematology
Faculty of Medicine, 4th Floor Commonwealth Building
Imperial College School of Medicine
Hammersmith Hospital
Du Cane Road
London W12 0NN
UK

Dr K. Lowry
Consultant in Intensive Care Medicine
Department of Intensive Care
Royal Victoria Hospital
Grosvenor Road
Belfast, BT12 6BA
Northern Ireland
UK

Dr L. Martin
Service d'Anesthésie-Réanimation
Centre Hospitalier de Bicêtre
94275 Le Kremlin Bicêtre
France

Dr Theresa McDonagh
Department of Medical Cardiology
University of Glasgow
Glasgow Royal Infirmary
10 Alexandra Parade
Glasgow G31 2ER
UK
Contributors

Dr D. Mesotten
Department of Intensive Care Medicine
University Hospital Gasthuisberg
University of Leuven
B-3000 Leuven
Belgium

Dr V. Minville
Service d’Anesthésie-Réanimation
Centre Hospitalier de Bicêtre
94275 Le Kremlin Bicêtre
France

Prof. Michael R. Pinsky
University of Pittsburgh School of Medicine
606 Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15261
USA

Dr H.K.F. van Saene
Consultant/Reader in Medical Microbiology
Department of Medical Microbiology
University of Liverpool
Duncan Building
Daulby Street
Liverpool L69 3GA
UK

Dr R.E. Sarginson
Department of Anaesthesia and Intensive Care
Royal Liverpool Children’s Hospital Alder Hey
Eaton Road, West Derby
Liverpool
Merseyside L12 2AP
UK

Prof. Dr Wolfgang Schlack
Leitender Oberarzt
Klinik fur Anaesthesiologie
Universitatsklinikum Dusseldorf
Moorenstrasse 5
40225 Dusseldorf
Germany
Contributors

Prof. Dr C. Stein
Direktor, Klinik für Anaesthesiologie
Campus Benjamin Franklin
Freie Universität Berlin
Hindenburgdamm 30
D-12200 Berlin
Germany

Dr B. Sweeney
Department of Anaesthesia
Royal Bournemouth Hospital
Castle Lane East
Bournemouth
Dorset BH7 7DW
UK

Dr N. Taylor
Department of Medical Microbiology
University of Liverpool
Duncan Building
Daulby Street
Liverpool L69 3GA
UK

Dr I. Vanhorebeek
Department of Intensive Care Medicine
University Hospital Gasthuisberg
University of Leuven
B-3000 Leuven
Belgium

Prof. Jean-Louis Vincent
Head, Department of Intensive Care
Erasme Hospital
Route de Lennick 808
B-1070 Brussels
Belgium

Dr C. Zöllner
Klinik für Anaesthesiologie
Campus Benjamin Franklin
Freie Universität Berlin
Hindenburgdamm 30
D-12200 Berlin
German